Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 6;22:498. doi: 10.1186/s12885-022-09595-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 14 — Expression levels of TUBA1C in glioma and normal tissues. TUBA1C expression in gliomas of different histology (A) and different WHO subtypes (B). TUBA1C expression in patients with different IDH mutation statuses (C) and different WHO subtypes (D). TUBA1C expression in patients with different 1p/19q codeletion statuses (E) and different WHO subtypes (F). TUBA1C expression in patients with different IDH mutation statuses and 1p/19q codeletion statuses (G) and different ages (H). TUBA1C expression in patients with different progression statuses (I) and different WHO subtypes (J). K TUBA1C expression in normal (left), low-grade glioma (middle) and high-grade glioma (right) tissue. Scale bars = 50 μm. Survival probability in the groups with different TUBA1C expression levels in all WHO subtypes of primary glioma (L) and recurrent glioma (M). Survival probability in the groups with different TUBA1C expression levels in WHO grade II primary glioma (N) and recurrent glioma (O). Survival probability in the groups with different TUBA1C expression levels in WHO grade III primary glioma (P) and recurrent glioma (Q). Survival probability in the groups with different TUBA1C expression levels in WHO grade IV primary glioma (R) and recurrent glioma (S)